Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia

NCT01379352 | Completed

• 1 other identifier: 2011-04-015
• Study Type: observational
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may also be different according to the preoperative hepatic function as measured by MELD score during prehepatic phase, or graft to recipient body weight ratio (GRWR) during neohepatic phase. Therefore, the investigators are trying to investigate the difference of vecuronium requirements according to the phase of surgery or MELD score, GRWR.

Conditions

Liver Transplantation

Keywords

liver transplantation; vecuronium

Outcome Measures

Primary Outcomes (3)

• vecuronium requirements during preanhepatic phase

  total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during preanhepatic phase

  during prehepatic phase of liver transplantation

• vecuronium requirements during anhepatic phase

  total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during anhepatic phase

  during anhepatic phase of liver transplantation

• vecuronium requirements during neohepatic phase

  total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during neohepatic phase

  during neohepatic phase of liver transplantation

Study Arms (2)

High MELD group

Preoperative MELD score greater than 20

Low MELD group

Preoperative MELD score lesser than 20

Eligibility Criteria

• Age: 20 Years - 69 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing elective living donor liver transplantation

You may qualify if:

• patients undergoing elective living donor liver transplantation

You may not qualify if:

• patients who can not undergo train-of-four test due to central or peripheral neuromuscular disease.
• patients with severe cardiopulmonary diseases.
• patients who received transfusion with more than 10 units of packed red blood cells.
• primary non-functioning graft immediately after reperfusion of the graft.
• patients who administered drugs that influences the metabolism of vecuronium (such as anticonvulsant: phenytoin, carbamazepine, primidone, sodium valproate)
• patients undergoing cadaver donor liver transplantation

Sponsors & Collaborators

• Samsung Medical Center: lead

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

Location

Study Officials

• Gaab Soo Kim, M.D.,Ph.D.

  Samsung Medical Center

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 21, 2011
• First Posted: June 23, 2011
• Study Start: June 1, 2011
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: December 25, 2013

Record last verified: 2013-12

Locations

KR (1)